ConductScience.org, home

Paper36966349

Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study.

Kal Omar R and 2 others. Trials, 2023. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study. Papers, record 36966349. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36966349

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study.
PubMed
Journal
Trials
PubMed
Year
2023
PubMed
Publication types
Clinical Trial Protocol, Journal Article
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.52
iCite
Revised in PubMed
2025-01-03
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kal Omar RRuba
2Hagström AAnnahttps://orcid.org/0000-0001-8254-7031
3Stålhammar GGustav

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MelatoninMajor topic
MelanomaMajor topic
Skin NeoplasmsMajor topic
Uveal NeoplasmsMajor topic
Adult
Humans
Randomized Controlled Trials as Topic
Clinical Trials, Phase III as Topic
Uveal Melanoma

Source PubMed

Download CSV of topics

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
SLS-971390The Swedish Society of MedicinePubMed
ME2019-0036The Royal Swedish Academy of SciencesPubMed
20 0798 FkCancerfondenPubMed
RS-2019-1138Region StockholmPubMed
2022-05-02The Swedish Eye FoundationPubMed
FS-2021-0010Karolinska InstitutetPubMed

Source PubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT05502900Adjuvant Melatonin for Uveal MelanomaBackgroundYes

Source ClinicalTrials.gov

Download CSV of trials

References60

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128823399Uveal Melanoma Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis.Ophthalmology2018https://conductscience.org/library/papers/28823399PubMed
217418968Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119).Int J Radiat Oncol Biol Phys2007https://conductscience.org/library/papers/17418968PubMed
325813452American Joint Committee on Cancer Classification of Uveal Melanoma (Anatomic Stage) Predicts Prognosis in 7,731 Patients: The 2013 Zimmerman Lecture.Ophthalmology2015https://conductscience.org/library/papers/25813452PubMed
48570130Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone.Oncology1996https://conductscience.org/library/papers/8570130PubMed
535413810The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature.BMC Cancer2022https://conductscience.org/library/papers/35413810PubMed
625058347Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing.Br J Cancer2014https://conductscience.org/library/papers/25058347PubMed
79067962Melatonin inhibits growth of cultured human uveal melanoma cells.Melanoma Res1997https://conductscience.org/library/papers/9067962PubMed
832258021BAP1 Immunoreactivity Correlates with Gene Expression Class in Uveal Melanoma.Ocul Oncol Pathol2020https://conductscience.org/library/papers/32258021PubMed
927822007Trends in incidence, survival, and management of uveal melanoma: a population-based study of 7,516 patients from the Surveillance, Epidemiology, and End Results database (1973-2012).Clin Ophthalmol2016https://conductscience.org/library/papers/27822007PubMed
105067774Melatonin and parkinsonism.JAMA1972https://conductscience.org/library/papers/5067774PubMed
111531290A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988.Arch Ophthalmol1992https://conductscience.org/library/papers/1531290PubMed
1210928160A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.Anticancer Res2000https://conductscience.org/library/papers/10928160PubMed
1316596311The anti-tumor activity of pineal melatonin and cancer enhancing life styles in industrialized societies.Cancer Causes Control2006https://conductscience.org/library/papers/16596311PubMed
1420413675An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma.J Mol Diagn2010https://conductscience.org/library/papers/20413675PubMed
1530910871Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm.Br J Ophthalmol2020https://conductscience.org/library/papers/30910871PubMed
1618505083Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.Anticancer Res2008https://conductscience.org/library/papers/18505083PubMed
178989723Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma.J Pineal Res1996https://conductscience.org/library/papers/8989723PubMed
187334363Effect of melatonin on experimental tumors under different photoperiods and times of administration.J Neural Transm1981https://conductscience.org/library/papers/7334363PubMed
1931952224Melatonin-Induced Cytoskeleton Reorganization Leads to Inhibition of Melanoma Cancer Cell Proliferation.Int J Mol Sci2020https://conductscience.org/library/papers/31952224PubMed
204028009Effect of melatonin on B16 melanoma growth in athymic mice.Cancer Res1985https://conductscience.org/library/papers/4028009PubMed

See all 60 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42065061Melatonin in Integrative Oncology: Biological Mechanisms, Therapeutic Evidence and Implementation Strategies.Oncol Res2026https://conductscience.org/library/papers/42065061PubMed
41737289Current Therapies and Potential Strategies for Uveal Melanoma.Drugs Drug Candidates2025https://conductscience.org/library/papers/41737289PubMed
40305352Melatonin MT1 Receptor Expression in Luminal Invasive Ductal Breast Carcinoma in Postmenopausal Women.Biomolecules2025https://conductscience.org/library/papers/40305352PubMed
38911030The Role and Therapeutic Potential of Melatonin in Degenerative Fundus Diseases: Diabetes Retinopathy and Age-Related Macular Degeneration.Drug Des Devel Ther2024https://conductscience.org/library/papers/38911030PubMed

Download CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36966349

GET https://conductscience.org/api/papers/v1/36966349/references?page=2